ERBB2 and breast carcinoma: Mevalonate was found to constitute an escape mechanism of survival and growth in HER2+ breast cancer models resistant to anti-HER2 therapies, partly through the activation of downstream YAP (Yes-associated protein)/TAZ (transcriptional coactivator with PDZ-binding motif)-Survivin signaling particularly through farnesyl pyrophosphate/geranylgeranyl pyrophosphate (83).